
Verge Genomics
Verge Genomics is a YC Summer 2015 (S15) company. Team of 50.
About Verge Genomics
Summary
Verge Genomics builds AI foundation models trained on one of the largest proprietary multimodal brain datasets in the field, covering molecular, proteomic, genomic, and clinical data from thousands of patients, to drive drug discovery for neurological diseases. Its platform predicts which targets to drug and which patients will respond, replacing broad trial enrollment with precision patient stratification. The work it replaces is conventional trial-and-error drug discovery and large, underpowered clinical trials.
Go-to-market
Verge Genomics operates as a drug developer in its own right while also pursuing partnerships, targeting pharmaceutical and biotech organizations that run neuroscience clinical programs and need patient-stratification or target-identification capabilities.
From the Y Combinator listing
We use human data and AI to develop better drugs faster.
Verge uses artificial intelligence and human data to develop better drugs faster. Verge has an end-to-end technology-driven drug discovery and development platform, featuring one of the field’s largest and most comprehensive proprietary patient genomics datasets from human tissue. Verge uses machine learning to mine this data and develops these insights into new drugs using it’s human-centric biology and chemistry platforms.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- 50
- Active
- Growth
Founders (1)
- Alice Zhang
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works